Literature DB >> 19821188

Pain management and substance abuse: a national dilemma.

Jeannine Catalano1.   

Abstract

Pain is the most common reason for medical care in the United States (Vukmir, 2004), with 32.8% of the U.S. population experiencing persistent or chronic pain symptoms. Undertreatment of pain is pervasive, as Congress declared 2001 to 2010 "the decade of pain control in research" and pharmaceutical companies responded with more effective medications to fight pain. However, nonmedical use and abuse of prescription pain medication has risen at an alarming rate in the United States within the past 5 years, especially among adolescents. The number of those abusing prescription drugs exceeds even combined numbers of those abusing cocaine, heroin, inhalants, and hallucinogens. This article examines the intersection of policies addressing nonmedical use and abuse of prescription pain medications and effects of enforcement strategies and policy direction on pain patients. Alternative policy direction and enforcement strategies are discussed.

Entities:  

Mesh:

Year:  2009        PMID: 19821188     DOI: 10.1080/19371910802679010

Source DB:  PubMed          Journal:  Soc Work Public Health        ISSN: 1937-190X


  3 in total

1.  Role of key informants and direct patient interviews in epidemiological studies of substance abuse.

Authors:  Theodore J Cicero; Matthew S Ellis; Alethea Paradis; Zachary Ortbal
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-12-09       Impact factor: 2.890

2.  Can we build an efficient response to the prescription drug abuse epidemic? Assessing the cost effectiveness of universal prevention in the PROSPER trial.

Authors:  D Max Crowley; Damon E Jones; Donna L Coffman; Mark T Greenberg
Journal:  Prev Med       Date:  2014-02-09       Impact factor: 4.018

3.  Self-management of pain among people who inject drugs in Vancouver.

Authors:  Pauline Voon; Cody Callon; Paul Nguyen; Sabina Dobrer; Julio Montaner; Evan Wood; Thomas Kerr
Journal:  Pain Manag       Date:  2014-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.